Professor Alison H Banham Facility Manager: Dr Amanda Anderson Level 4 Academic Block, John Radcliffe Hospital amanda.anderson@ndcls.ox.ac.uk



Radcliffe Department of Medicine

- Antibodies are critical research tools in many immunological assays
- Therapeutic antibodies are among the most successful modern drugs used to treat human disease
- The global antibody market was reported to top \$100 billion in 2017
- We aim to apply our expertise to allow other researchers to find, select, produce, validate and use antibodies successfully in their research
- Our primary focus will be the production, characterisation and validation of novel monoclonal antibodies (mAbs)

Concerns widely raised about the quality of antibodies used for research

Reports that up to 50% of commercially available antibodies fail even basic reactivity and specificity tests

This 'buyer beware' culture leads to: wasted research time wasted money errors in the scientific literature

Estimated that the US alone wasted \$350 million on 'bad' antibodies in 2015

A global standards institute report found almost one third of young scientists did not validate their antibodies in 2016

Nature 521, 274–276 (21 May 2015)

Professor Alison Banham & Dr Amanda Anderson


- A combined total of >40 years experience of producing & characterising monoclonal antibodies
- Members of the European Antibody Network (EuroMabNet), Prof Banham, their current Vice President
- Contributed to the EuroMabNet Antibody Validation Guidelines and Antibody Validation Workshops
- Antibodies used as research tools, diagnostic/prognostic biomarkers and therapeutics
- Experience of licensing antibodies for research and *in vitro* diagnostic use to commercial suppliers
- Experience of patenting antibodies, including therapeutics

Examples of Previous mAb Projects

Target	Collaborator(s) outside of NDCLS	
BCL11A _{XL} ELTD1* FMIP FOXP1 FOXP2	Prof Martin Dyer Profs Adrian Harris, Susan Lea, Penny Handford Prof Tony Whetton	Leicester Oxford Manchester
FOXP3 FOXP4	Dr Giovanna Roncador	Madrid
Jagged1* MORC4 NFIL3	Profs Adrian Harris, Susan Lea, Penny Handford	Oxford
Notch1* p53 P53/HLA-A2 PASD1	Profs Adrian Harris, Susan Lea, Penny Handford Dr Bart Cornelissen 2*	Oxford Oxford
Strap	Prof Nick La Thangue	Oxford


* Therapeutic projects

FOXP1 Expression Identifies High-Risk Lymphoma Patients With Smaller Isoform Expression




High FOXP1 predicts poor outcome Banham 2005 Clin Cancer Res

FOXP3: A Marker of Regulatory T cells



- With Dr Giovanna Roncador (Madrid) we generated the first FOXP3 mAbs
- We characterised the human FOXP3 population, studying both their frequency in the peripheral blood (Prof Fiona Powrie) and their suppressor function (Prof Enzo Cerundolo)

Antibodies Against MHC Class I Presented Peptides to Target the Intracellular Proteome



- Intracellular proteins are inaccessible to classical antibodies
- However, peptides derived from intracellular proteins, such as p53, are presented by MHC class I on the cell surface
- T-cell receptor mimic antibodies can be used to therapeutically target such MHC class I presented peptides and to image tumours *in vivo*

- Identification of existing commercially available antibodies
- Antigen design and production: peptides & recombinant proteins
- Murine monoclonal antibody production (fusion)
- Antibody screening: reactivity with antigen, typically by ELISA
- Antibody validation: positive vs negative cells, transfected cells, siRNA
- Hybridoma cell line cloning
- Hybridoma culture and production of mAb containing supernatant
- Antibody purification
- Antibody isotyping
- Basic training in antibody-based techniques e.g. WB, IHC, IF, IP

- Resources: a 2 year position supporting an experienced postdoctoral scientist, Dr Amanda Anderson, with both research and industrial experience of antibody production and characterisation who will day-to-day manage and deliver the Facility
- Post funded from existing NDCLS-RDM Antibody Royalty Income
- We have established this activity as a Small Research Facility
- We aim to recover costs by charging users and/or by commercially licensing the antibodies produced for research and *in vitro* diagnostic use
- Our aim is to make the post sustainable in the longer term as it is not currently supported by the NIHR Oxford BRC that supports the other HIDI platforms

Radcliffe Department of

I am happy to take any questions



Radcliffe Department of Medicine